Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nam

Showing results (31-40 of 69) with videos related to

Pageof 7
Sort By:
RMD Open|April 10, 2024
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody testAndrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, et al.
Rheumatology (Oxford, England)|January 8, 2021
In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritisAndrea Di Matteo, Kulveer Mankia, Jacqueline L Nam, et al.
Arthritis Research & Therapy|January 19, 2022
Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational studyLeticia Garcia-Montoya, Jacqueline L Nam, Laurence Duquenne, et al.
The Lancet. Global Health|August 8, 2020
Impact of COVID-19 on maternal and child healthElizabeth M McClure, Mary V Kinney, Susannah Hopkins Leisher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 26, 2020
Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid ArthritisAndrea Di Matteo, Kulveer Mankia, Laurence Duquenne, et al.
The Lancet. Rheumatology|January 24, 2024
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort studyLeticia Garcia-Montoya, Jing Kang, Laurence Duquenne, et al.
Rheumatology (Oxford, England)|December 10, 2024
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary careHeidi J Siddle, Michelle Wilson, Jacqueline L Nam, et al.
Frontiers in Medicine|March 9, 2018
Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory ArthritisSarah Twigg, Elena Nikiphorou, Jackie L Nam, et al.
Science Advances|September 17, 2019
Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channelsMark A Skylar-Scott, Sebastien G M Uzel, Lucy L Nam, et al.
RMD Open|April 9, 2026
Persistent arthritis develops in joints previously affected by palindromic flares: a longitudinal study investigating the transition from palindromic rheumatism to rheumatoid arthritisDidem Sahin, Rahaymin Chowdhury, Andrea Di Matteo, et al.
Pageof 7

Showing results (31-40 of 69) with videos related to

Sort By:
Pageof 7
RMD Open|April 10, 2024
Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody testAndrea Di Matteo, Kulveer Mankia, Leticia Garcia-Montoya, et al.
Rheumatology (Oxford, England)|January 8, 2021
In anti-CCP+ at-risk individuals, radiographic bone erosions are uncommon and are not associated with the development of clinical arthritisAndrea Di Matteo, Kulveer Mankia, Jacqueline L Nam, et al.
Arthritis Research & Therapy|January 19, 2022
Prioritising referrals of individuals at-risk of RA: guidance based on results of a 10-year national primary care observational studyLeticia Garcia-Montoya, Jacqueline L Nam, Laurence Duquenne, et al.
The Lancet. Global Health|August 8, 2020
Impact of COVID-19 on maternal and child healthElizabeth M McClure, Mary V Kinney, Susannah Hopkins Leisher, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 26, 2020
Third-Generation Anti-Cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Individuals at Risk of Rheumatoid ArthritisAndrea Di Matteo, Kulveer Mankia, Laurence Duquenne, et al.
The Lancet. Rheumatology|January 24, 2024
Factors associated with resolution of ultrasound subclinical synovitis in anti-CCP-positive individuals with musculoskeletal symptoms: a UK prospective cohort studyLeticia Garcia-Montoya, Jing Kang, Laurence Duquenne, et al.
Rheumatology (Oxford, England)|December 10, 2024
A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary careHeidi J Siddle, Michelle Wilson, Jacqueline L Nam, et al.
Frontiers in Medicine|March 9, 2018
Comorbidities in Anti-Cyclic Citrullinated Peptide Positive At-Risk Individuals Do Not Differ from Those Patients with Early Inflammatory ArthritisSarah Twigg, Elena Nikiphorou, Jackie L Nam, et al.
Science Advances|September 17, 2019
Biomanufacturing of organ-specific tissues with high cellular density and embedded vascular channelsMark A Skylar-Scott, Sebastien G M Uzel, Lucy L Nam, et al.
RMD Open|April 9, 2026
Persistent arthritis develops in joints previously affected by palindromic flares: a longitudinal study investigating the transition from palindromic rheumatism to rheumatoid arthritisDidem Sahin, Rahaymin Chowdhury, Andrea Di Matteo, et al.
Pageof 7